Royal Brompton Hospital

Running trials

• Not yet recruiting

  SPutum Induction and Nebuliser deviCEs for Patients With CF

  NCT07879651· Source

• Recruiting

  Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Sclerosis

  NCT07502677· Source

• Recruiting

  Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study

  NCT06939374· Source

• Recruiting

  A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06968845· Phase 2· Source

• Not yet recruiting

  A Prospective Study of Advanced Diagnostics in People With an Unclear Diagnosis of Cystic Fibrosis

  NCT07402434· Source

• Recruiting

  Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

  NCT07230288· Phase 2· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Source

• Recruiting

  A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications

  NCT07332117· Source

• Recruiting

  Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

  NCT06891755· Source

• Recruiting

  A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979375· Phase 2· Source

• Recruiting

  A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979362· Phase 2· Source

• Active, not recruiting

  A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06736990· Phase 2· Source

• Recruiting

  A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring

  NCT06797206· Source

• Active, not recruiting

  A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)

  NCT06962852· Phase 1/2· Source

• Recruiting

  Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis

  NCT06940531· Source

• Active, not recruiting

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

  NCT06925750· Phase 2· Source

• Recruiting

  An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  NCT06951217· Phase 2· Source

• Recruiting

  A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

  NCT06846554· Phase 2· Source

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

  NCT06588686· Phase 2· Source

• Active, not recruiting

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

  NCT06460506· Phase 3· Source

• Recruiting

  Exploring How Viral Infections Affect People With Chronic Lung Disease

  NCT06625944· Source

• Enrolling by invitation

  Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

  NCT06472362· Source

• Recruiting

  First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System

  NCT06423690· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Source

• Recruiting

  A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

  NCT06559150· Phase 2· Source

• Active, not recruiting

  YOGA-CF (Yoga Outcomes Get Assessed in Cystic Fibrosis)

  NCT06120465· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Source

• Recruiting

  An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

  NCT06035120· Source

• Active, not recruiting

  Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)

  NCT06181240· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Source

• Active, not recruiting

  Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema

  NCT05949645· Source

• Recruiting

  RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure

  NCT05568069· Source

• Active, not recruiting

  Closed-loop for People Living With Cystic Fibrosis Related Diabetes

  NCT05562492· Source

• Recruiting

  Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

  NCT05496998· Source

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Source

• Recruiting

  The CATALINA Study

  NCT05008081· Source

• Active, not recruiting

  The Euro-CRAFT Registry

  NCT05805462· Source

• Active, not recruiting

  Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

  NCT05570058· Phase 2· Source

• Recruiting

  The "Global Paradise System" Registry

  NCT05027685· Source

• Recruiting

  Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

  NCT05102019· Source

• Active, not recruiting

  A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT04819100· Phase 3· Source

• Active, not recruiting

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

  NCT07218029· Phase 3· Source

• Enrolling by invitation

  Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

  NCT04848506· Phase 2/3· Source

• Active, not recruiting

  Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

  NCT04763200· Source

• Active, not recruiting

  Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)

  NCT04602468· Phase 4· Source

• Enrolling by invitation

  A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

  NCT03683186· Phase 3· Source

• Active, not recruiting

  REDUCER-I: An Observational Study of the Neovasc Reducer™ System

  NCT02710435· Source

• Active, not recruiting

  HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy

  NCT01915615· Source

• Active, not recruiting

  Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank

  NCT02951416· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Cystic fibrosis5 recruiting
• Idiopathic pulmonary fibrosis5 recruiting
• COPD3 recruiting
• Heart failure3 recruiting
• Coronary artery disease2 recruiting
• High blood pressure2 recruiting
• Pulmonary arterial hypertension2 recruiting
• ALS (motor neurone disease)1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Lung cancer1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

  NCT06664801· Phase 2· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Source

• Completed

  Radial Artery Assessment in Surgical Coronary Revascularisation

  NCT06433960· Source

• Completed

  A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis

  NCT06478706· Phase 2· Source

• Completed

  Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF

  NCT06468527· Phase 2· Source

• Completed

  Cough Reduction in IPF With Nalbuphine ER

  NCT05964335· Phase 2· Source

• Withdrawn

  A40 Expiratory Flow Limitation Registry

  NCT04419428· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Source

• Withdrawn

  A Study to Investigate Leramistat in Patients With IPF

  NCT05951296· Phase 2· Source

• Completed

  A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

  NCT05954988· Phase 1· Source

• Completed

  Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

  NCT05882357· Phase 3· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Source

• Completed

  A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

  NCT05668741· Phase 1/2· Source

• Terminated

  Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

  NCT05667662· Phase 2· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

  NCT05186818· Phase 3· Source

• Completed

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

  NCT05153317· Phase 3· Source

• Completed

  A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

  NCT04896008· Phase 3· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Source

• Completed

  Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)

  NCT04559464· Source

• Completed

  Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

  NCT04533022· Phase 2· Source

• Completed

  Benralizumab Exacerbation Study

  NCT04102800· Phase 4· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· Source

Trial sites

• Royal Brompton Hospital64 trials
• Royal Brompton Hospital, Department of Cystic Fibrosis (Adult)1 trial
• Royal Brompton Hospital /ID# 2780071 trial
• Royal Brompton Hospital, Pulmonary Hypertension Service, Sydney Street1 trial
• Royal Brompton Hospital (Site 1206)2 trials
• Royal Brompton Hospital (Site 1804)2 trials
• The Royal Brompton Hospital1 trial
• The Royal Brompton Hospital - Respiratory CRF2 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Asthma64 works · 2 trials
• Cystic fibrosis49 works · 18 trials
• Idiopathic pulmonary fibrosis28 works · 18 trials
• COPD23 works · 7 trials
• Pulmonary arterial hypertension13 works · 8 trials